Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00613223 | Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | PHASE1 | COMPLETED | 49 | — | — | Feb 1, 2008 | May 1, 2011 | Feb 20, 2013 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Vandetanib and Etoposide | EXPERIMENTAL | Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide. |
| Name | Type | Description |
|---|---|---|
| Vandetanib and Etoposide | DRUG | Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle. |
Inclusion Criteria: Patients have baseline evaluations ≤14days prior to 1st dose of study drug unless otherwise specified * Patients with confirmed malignant glioma (MG) who are recurrence/relapse * Patients may not have stereotactic tumor biopsy \< 1 week or surgical resection or open biopsy \< 4...